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SObjective: This study aimed to determine whether preresection serum CRP level independently predicts sur-
vival among patients with resectable non–small cell lung cancer.
Methods:Clinical, pathologic, and laboratory data from 300 patients operated on for non–small cell lung cancer
in a single institution were studied in univariate and multivariate survival analyses. Validation was sought in
another cohort of 68 similar patients from another institution.
Results: In the main cohort, preoperative CRP value was 3 mg/L or lower in 136 patients (45.3%), between 4
and 20 mg/L in 89 (29.7%), and greater than 20 in 64 (21.3%). CRP level was significantly associated with
chronic bronchitis, hypoalbuminemia, pathologic stage, and peritumoral vascular emboli. Overall, 5-year sur-
vivals of patients with preoperative CRP 3 mg/L or lower, between 4 and 20 mg/L, and greater than 20 mg/L
were 55.6%, 45.6%, and 40.0%, respectively (P ¼ .0571). In multivariate analysis, CRP level greater than
20 was significantly associated with survival, but with significant interaction between CRP level and disease
stage (P ¼ .02). Patients in stage I or II disease with CRP levels greater than 20 had worse survival than did
patients with undetectable CRP (adjusted hazard ratio, 1.874; 95% confidence interval, 1.039–3.381); the
difference was not significant in stages III and IV. In the validation series, CRP level greater than 20 mg/L
also predicted worse survival (P ¼ .018).
Conclusions: Preoperative CRP level greater than 20 mg/L is significantly associated with worse survival than
undetectable CRP in patients with stage I or II non–small cell lung cancer. (J Thorac Cardiovasc Surg
2011;142:1161-7)The role of systemic inflammation in patients with cancer
is being increasingly investigated.1,2 Proinflammatory
cytokines and associated growth factors are involved in
carcinogenesis through their effects on tumor cell growth,
survival, proliferation, and migration.3 In addition, tumor
cells themselves release inflammatory cytokines.3 It has
been shown that slight elevation of inflammatory markers
is associated with the occurrence of non–small cell lung
cancer (NSCLC).4 Lung cancer is frequently associated
with chronic obstructive pulmonary disease, which in-
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The Journal of Thoracic and Carof smoking.5 Chronic obstructive pulmonary disease is
also associated with systemic inflammation and shares
several mechanisms with lung cancer, including airways
inflammation protease/antiprotease imbalance, oxidative
stress, and abnormal repair mechanisms.6 In chronic ob-
structive pulmonary disease, markers of systemic inflam-
mation are related to survival and nutritional status.6
Serum C-reactive protein (CRP), a well known and
routinely measured marker of chronic inflammation, is
produced in the liver in response to elevated levels of proin-
flammatory cytokines, in particular interleukin 1, tumor
necrosis factor a, and mainly interleukin 6.7 In NSCLC,
the tumoral cells are able to release interleukin 6 and tumor
necrosis factor a, as assessed by experimental studies on
lung cancer cell lines and expression studies on resected
specimens.8-10
CRP has been identified as a prognostic factor in several
tumors.11,12 Its relationship with prognosis has also been
suggested in advanced NSCLC13,14 and, to a lesser extent
in resectable disease.15,16 In that context, CRP levels are
related to several clinicopathologic features (mainly
tumor size), which makes it difficult to determine their
respective roles in survival.15
The aim of this study was to determine whether preresec-
tion serumCRP level is an independent predictor of survivaldiovascular Surgery c Volume 142, Number 5 1161
Abbreviations and Acronyms
CI ¼ confidence interval
CRP ¼ C-reactive protein
CT ¼ computed tomography
NSCLC ¼ non–small cell lung cancer
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Sfor resected NSCLC. We analyzed data of 2 cohorts of con-
secutive patients undergoing surgery for NSCLC in 2
French Institutions.
MATERIALS AND METHODS
A 2-step process was followed. First, data from a prospective cohort of
all consecutive patients who underwent lung resection at Ho^tel-Dieu Uni-
versity Hospital in Paris were analyzed (main cohort). Then generalizabil-
ity of results was assessed in another cohort of patients with similar
inclusions characteristics cared for in another center (validation cohort).
Informed consent was obtained from all patients. The research was con-
ducted according to recommendations outlined in the Helsinki Declaration.
Institutional review board approval was obtained (CPP Ile de France II, No.
2008-133).
Serum CRP levels were measured in laboratories of both institutions by
nephelometry as a part of routine presurgical laboratory examinations.
Lower detection limit was 3 mg/L, which was chosen as a cutoff. On the
basis of clinical relevance, a second cutoff was set at 20 mg/L.
Long-term survivals of patients in both cohorts were assessed retrospec-
tively by direct telephonic patient or family (in the case of deceased pa-
tients) interviews. When no clinical follow-up was available, information
on vital status was obtained through the municipality of birth of the patient.
Main Cohort
All patients undergoing major lung resection for NSCLC between June
15, 2001, andMay 15, 2002, in the Thoracic Surgery Department of Ho^tel-
Dieu Hospital, Paris, France, were included in this study. Patients were
excluded if any of the following features were present: antibiotic treatment
in the week before hospital admission, fever with temperature greater than
38C, purulent sputum, or lung consolidation. Patients characteristics,
treatment procedures, and short-term outcomes were prospectively col-
lected with a standardized case report form, which was initially designed
to study the determinants of postoperative respiratory complications.17,18
For the purposes of this study, the variables shown in Table 1 were ana-
lyzed. In particular, we recorded the following: age, sex, body mass index,
medical history including tobacco consumption, lung function, indication
for lung resection, CRP level, white blood cell count, chest radiography,
and albumin and prealbumin levels. Data on long-term outcomes were
obtained retrospectively.
Validation Cohort
The validation clinical series was obtained by retrospective analysis of
clinical, pathologic, and laboratory files of patients undergoing surgery for
NSCLC between April 1, 2005, and May 31, 2006, in the Department of
Thoracic Surgery of Strasbourg University Hospital, France.
Patient Management
In both centers, the patient management was similar. Staging protocol
involved chest radiography, fiberoptic bronchoscopy, thoracic and upper
abdominal computed tomography (CT). Cerebral CT scans were per-
formed in the presence of neurologic symptoms or if N2 disease was
suspected. Positron emission tomographic scans were seldom performed
before 2006 at either institution.1162 The Journal of Thoracic and Cardiovascular SurMediastinal Lymph Node Assessment and
Neoadjuvant Chemotherapy
In the case of clinical suspicion of N2 disease (lymph node short axis>1
cm on CT scan), mediastinal staging was carried out by either transbron-
chial needle aspiration or, more frequently, mediastinoscopy. In rare cases
the disease was staged N2 on the basis of CT and positron emission tomo-
graphic scans without histologic confirmation because of the presence of
bulky homolateral lymph nodes. If N2 disease was confirmed, neoadjuvant
chemotherapy was administered. Patients were then considered to have
operable disease in the presence of clinical response or stable disease. In
cases of progressive disease, surgery was not proposed and the patient
was excluded from this analysis.
Surgical Procedure, Pathologic Data, and Adjuvant
Treatment
Surgery was carried out through standard posterolateral thoracotomy.
Full nodal dissection was carried out in all cases. Collected pathologic
data included histologic type; T, N, and M parameters; and tumor stage
according to the 1997 Union for International Cancer Control, American
Thoracic Society, and American College of Chest Physicians lung cancer
staging system. Information about the presence of vascular or lymphatic
tumor emboli was also collected. Adjuvant radiotherapy or chemotherapy
was proposed on an individual basis after multidisciplinary evidence-
based discussions with patients under the care of their referring
physicians.
Data Analysis
Characteristics of patients were describedwith numbers and percentage.
The characteristics associated with CRP levels were identified with c2 or
Fisher Exact tests as appropriate. Survival was described according to
the Kaplan-Meier method. Survivals were compared according to the char-
acteristics of participants with log-rank tests. All the variables associated
with survival with a P value lower than .2 in univariate analysis were en-
tered into the multivariate analysis with the Cox model. To further control
for confounding, we also adjusted on a propensity score of having a CRP
level greater than 20 mg/L. To do so, we performed a logistic regression
model with CRP level greater than 20 mg/L as the dependent variable
with all variables that were recorded in a sufficient number of patients.
The multivariate analysis also included an interaction term between
CRP level and stage of the cancer to assess whether the effect of CRP varied
with stage of cancer. This interaction proved significant, so we have
presented the results separately for stages I and II and stages III and IV.
All the analyses were performed with the software R 2.10.1, a language
and environment for statistical computing. (R Foundation for Statistical
Computing, Vienna, Austria).RESULTS
Main Cohort
Among 347 patients undergoing lung resections for
NSCLC between June 2001 and May 2002 at Ho^tel-Dieu
Hospital, 47 were excluded from the analysis: 29 with infec-
tion at time of surgery and 18 because they were not living
in France (so follow-up was limited). Altogether, 300 pa-
tients were analyzed.
Preoperative, surgical, and pathologic data. An endo-
bronchial tumor was seen at fiberoptic bronchoscopy in
34.4% of cases; 8.5% of patients had a cavitary lesion on
preoperative CT scan. Induction treatments had been car-
ried out in 80 patients (68 chemotherapy, 12 radiotherapy).
Main indication for preoperative induction therapy was N2gery c November 2011
TABLE 1. Patient characteristics (main cohort)
Total (N ¼ 300)
C-reactive protein level (mg/L)
P value3 (N ¼ 136) 4–20 (N ¼ 89) >20 (N ¼ 64)
Men 255 (85%) 117 (47.4%) 76 (30.8%) 54 (21.9%) .9757
Age>70 y 77 (25.7%) 38 (50.7%) 21 (28%) 16 (21.3%) .7635
Body mass index (kg/m2) .2237
<18.5 25 (8.6%) 15 (62.5%) 5 (20.8%) 4 (16.7%)
18.5–25 151 (51.7%) 59 (40.7%) 49 (33.8%) 37 (25.5%)
25 116 (39.7%) 59 (51.3%) 35 (30.4%) 21 (18.3%)
Smoking history
Past or present smoking 284 (94.7%) 128 (46.7%) 85 (31%) 61 (22.3%) .9417
Cessation 2 wk before surgery 167 (59.2%) 74 (46.2%) 48 (30%) 38 (23.8%) .6975
Comorbid illness
Alcohol abuse 84 (28.1%) 42 (50.6%) 29 (34.9%) 12 (14.5%) .1233
Diabetes mellitus 38 (13.7%) 17 (44.7%) 11 (28.9%) 10 (26.3%) .9236
Angina history 33 (16%) 16 (48.5%) 12 (36.4%) 5 (15.2%) .4842
Stroke 13 (6.3%) 10 (76.9%) 2 (15.4%) 1 (7.7%) .2204
Lower limb atheroma 29 (14%) 18 (62.1%) 9 (31%) 2 (6.9%) .142
Respiratory status
Chronic bronchitis 201 (67%) 92 (47.9%) 58 (30.2%) 42 (21.9%) .9338
Chronic obstructive pulmonary disease 198 (66.4%) 80 (41.5%) 64 (33.2%) 49 (25.4%) .0186
American Society of Anesthesiologists score
I or II 190 (64.8%) 87 (47.3%) 52 (28.3%) 45 (24.5%) .4085
III or IV 103 (35.2%) 46 (46%) 35 (35%) 19 (19%)
Albumin<40 g/L 63 (22.8%) 11 (17.7%) 15 (24.2%) 36 (58.1%) <.0001
Prealbumin<200 mg/L 45 (18.4%) 5 (11.4%) 12 (27.3%) 27 (61.4%) <.0001
Right-sided procedure 178 (59.3%) 84 (49.4%) 53 (31.2%) 33 (19.4%) .3929
Type of resection
Lobectomy or bilobectomy 230 (76.7%) 112 (49.8%) 70 (31.1%) 43 (19.1%) .0582
Pneumonectomy 70 (23.3%) 24 (37.5%) 19 (29.7%) 21 (32.8%)
Chest wall resection or parietal pleura 18 (6%) 6 (33.3%) 3 (16.7%) 9 (50%) .0241
Histologic type 2 (100%) 0 (0%) 0 (0%) .0209
Epidermoid carcinoma 119 (39.7%) 45 (39.5%) 37 (32.5%) 32 (28.1%)
Adenocarcinoma 120 (40%) 61 (52.6%) 42 (36.2%) 13 (11.2%)
Basaloid carcinoma 1 (0.3%) 0 (0%) 0 (0%) 1 (100%)
Bronchoalveolar carcinoma 11 (3.7%) 7 (63.6%) 2 (18.2%) 2 (18.2%)
Large cell carcinoma 38 (12.7%) 16 (44.4%) 8 (22.2%) 12 (33.3%)
Mixed carcinoma 6 (2%) 3 (50%) 0 (0%) 3 (50%)
Large cell neuroendocrine carcinoma 3 (1%) 2 (66.7%) 0 (0%) 1 (33.3%)
Pathologic stage .0029
I 126 (42.4%) 74 (60.7%) 31 (25.4%) 17 (13.9%)
II 67 (22.6%) 25 (37.3%) 21 (31.3%) 21 (31.3%)
III 92 (31%) 33 (38.4%) 32 (37.2%) 21 (24.4%)
IV 12 (4%) 3 (27.3%) 3 (27.3%) 5 (45.5%)
Microvascular invasion
Vascular emboli 130 (43.6%) 2 (100%) 51 (40.2%) 50 (31.2%) .0433
Lymphatic emboli 76 (25.6%) 32 (43.2%) 26 (35.1%) 16 (21.6%) .67
All data represent numbers and percentages of patients.
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Sdisease (n ¼ 68), which was diagnosed on the basis of me-
diastinoscopy (n ¼ 48), transtracheal needle aspiration
(n ¼ 4), or imaging (n ¼ 16). All chemotherapy protocols
were platinum based. Operative mortality was 6.3%
(n ¼ 19).
Table 1 summarizes the main preoperative characteris-
tics and surgical and pathologic data, including CRP levels,The Journal of Thoracic and Carof all patients. CRP level of 3 mg/L or less was found in
136 patients(45.3%), and among patients with a detectable
CRP (n¼ 153), 89 (29.7%) had a CRP level between 4 and
20 mg/L and 64 (21.3%) had a level higher than 20 mg/L.
The CRP levels were associated with GOLD (Global
Initiative for Chronic Obstructive Lung Disease) stage II
chronic obstructive pulmonary disease (P ¼ .0186),diovascular Surgery c Volume 142, Number 5 1163
FIGURE 1. Kaplan-Meier estimates of survival. A, Overall survival in the main cohort. B, Survival curves of patients with stages I and II in the main cohort
according to the C-reactive protein (CRP) levels. C, Survival curves of patients with stages III and IV in the main cohort according to the C-reactive protein
levels. D, Survival curves in the validation cohort according to the C-reactive protein levels.
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Shypoalbuminemia (P<.0001), and hypoprealbuminemia
(P<.0001), as well as histologic type (P ¼ .0209), path-
ologic stage (P ¼ .0029), microvascular invasion
(P ¼ .0433), and chest wall resection (P ¼ .0241).
Long-term survival. At completion of the study (June
2010), 120 patients (40%) were alive and 180 (60%)
were dead. The median follow-up duration was 89.2
months (interquartile range, 82.6–92.9 months). For the
whole population, median survival was 54.9 months
(95% confidence interval [CI], 41.1–72.5 months). The
3-, 5-, and 7-year overall survivals were 57.8% (95%
CI, 52.4%–63.7%), 48.3% (95% CI, 42.9%–54.4%),
and 44.0% (95% CI, 38.6%–50.1%), respectively
(Figure 1, A).
The univariate survival analysis is reported in Table 2.
Factors associatedwith long-termsurvivalwere chronic bron-
chitis (P¼ .0136), hypoprealbuminemia (P¼ .0215), the type
of resection (P<.0001), the pathologic stage (P<.0001), and
the presence of vascular emboli (P ¼ .0381). CRP level cut-
offs of undetectable, higher than 3 mg/L, and higher than
20 mg/L tended to be associated with survival (P ¼ .0571),
with 5-year survivals of 55.6% (95% CI, 47.8%–64.8%),
45.6% (95% CI, 36.2%–57.5%), and 40.0% (95%
CI 29.4%–54.4%), respectively. Survival curves in stages I
and II on the one hand and in stage III and IV on the other
handare presented inFigure1 (B andC, respectively. In stages
I and II, patients with an undetectable CRP had a better sur-
vival than did those with a CRP greater than 20 mg/L and
those with a CRP between 4 and 20 (P ¼ .00245). In stages
III and IV, survival was not significantly different among
the CRP levels (P ¼ .475).
The results of the multivariate analysis are presented
in Table 3. Stage III-IV (P ¼ .0010), pneumonectomy1164 The Journal of Thoracic and Cardiovascular Sur(P ¼ .0008), CRP greater than 20 mg/L (P ¼ .0368),
and American Society of Anesthesiologists score III-IV
(P  .0270) were independent predictors of death in the
whole population. There was a statistically significant inter-
action between CRP level and stage of the cancer. Table 4
shows the adjusted hazard ratios for CRP levels according
to the stage of the cancer. In stages I and II, the patients
with CRP greater than 20mg/L had a significantly increased
adjusted hazard ratio of 1.874 (95% CI, 1.039–3.381) rela-
tive to patients with undetectable CRP, and those with
a CRP between 4 and 20 mg/L had a nonsignificantly
increased hazard ratio of 1.364 (95% CI, 0.824–2.257).
In stages III and IV, the association was inverse but not
significant: patients with a CRP greater than 20 mg/L had
a lower adjusted hazard ratio of 0.492 (95% CI, 0.233–
1.039) relative to those with undetectable CRP.
Validation Cohort
Sixty-eight patients were evaluated in the validation co-
hort. There were 11 women and 57 men. Mean age was
62.2  9.9 years. Ten pneumonectomies and 58 lobecto-
mies or bilobectomies were performed for NSCLC. Histo-
logic types were epidermoid carcinoma, adenocarcinoma,
large cell carcinoma, bronchoalveolar carcinoma, mixed
carcinoma, and large cell neuroendocrine carcinoma in
29, 23, 7, 6, 2, and 1 patients, respectively. Pathologic stages
were IA, IB, IIA, IIB, IIIA, IIIB, and IV in 13, 14, 1, 8, 23, 5,
and 2 cases, respectively.
CRP values of 3 mg/L or less were found in 24 (35.3%)
of 68 patients, 25 patients had a CRP value between 4 and
20 mg/L, and 20 had a CRP value greater than 20 mg/L.
The median of the detectable CRP values was 17.5 mg/L
(interquartile range 10–60.5 mg/L).gery c November 2011
TABLE 2. Effects of clinical, laboratory, and pathologic parameters
on survival in the whole population of the main cohort: Univariate
analysis
Variable Survival Lower Upper P value
Age .095
70 y 0.508 0.445 0.579
>70 y 0.41 0.312 0.539
Body mass index .104
<18.5 kg/m2 0.477 0.315 0.721
18.5–24.99 kg/m2 0.44 0.367 0.528
25 kg/m2 0.544 0.459 0.645
Sex .2707
Men 0.469 0.411 0.536
Women 0.562 0.432 0.732
Chronic bronchitis .0136
Yes 0.433 0.368 0.508
No 0.586 0.495 0.693
Albumin .0506
<40 g/L 0.39 0.283 0.538
40 g/L 0.523 0.46 0.596
Prealbumin .0215
<200 mg/L 0.368 0.248 0.547




No 0.472 0.382 0.583
Yes 0.488 0.423 0.564
Current or past smoker .1979
Yes 0.478 0.422 0.541
No 0.591 0.384 0.91
Atheroma .2792
No 0.435 0.316 0.599




I or II 0.526 0.459 0.603
III or IV 0.394 0.308 0.504
Resection <.0001
Lobectomy or bilobectomy 0.549 0.488 0.618
Pneumonectomy 0.261 0.173 0.392
C-reactive protein .0571
Undetectable 0.556 0.478 0.648
4–20 mg/L 0.456 0.362 0.575
>20 mg/L 0.400 0.294 0.544
Pathologic stage <.0001
I 0.696 0.62 0.782
II 0.381 0.279 0.521
III or IV 0.287 0.21 0.393
Histologic type .8353
Nonepidermoid 0.496 0.427 0.577
Epidermoid 0.471 0.388 0.571
Vascular emboli .0381
No 0.554 0.483 0.636
Yes 0.398 0.321 0.494
Lymphatic emboli .1179
No 0.514 0.452 0.586
Yes 0.403 0.305 0.533











American Society of Anesthesiologists score
III or IV vs I or II e 0.190 .0270
C-reactive protein
4–20 mg/L vs undetectable 0.310 0.257 .2276
>20 mg/L vs undetectable 0.628 0.301 .0368
Body mass index
>25 kg/m2 vs 18.5–25 kg/m2 0.081 0.178 .6497
18.5 vs>18.5–25 kg/m2 0.360 0.313 .2499
Age
>70 y vs 70 y 0.078 0.201 .7001
Lymphatic emboli
Yes vs no 0.030 0.199 .8786
Vascular emboli
Yes vs no 0.263 0.182 .1490
Smoking status
Smoker vs not a smoker 0.852 0.599 .1550
Chronic bronchitis
Yes vs no 0.324 0.200 .1048
Albumin
<40 g/L vs 40 g/L 0.006 0.378 .9876
Propensity score 0.483 0.765 .5278
Interactions with stage III or IV
C-reactive protein 4–20 mg/L 0.636 0.398 .1096
C-reactive protein>20 mg/L 1.338 0.438 .0023
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SAge (P ¼ .32), sex (P ¼ .84), extent of resection
(P ¼ .21), and histologic type (epidermoid vs adenocarci-
noma or large cell carcinoma, P¼ .069) failed to be associ-
ated with survival. Stage (P ¼ .012) and CRP level
(P¼ .021) were predictors of survival in univariate analysis.
Patients with CRP levels of 3 mg/L or less had a 5-year sur-
vival of 82.7% (95% CI, 62.9%–93.1%), as compared
with 51.7% (95% CI, 34.6%–77.4%) and 40.0% (95%
CI, 23.4%– 68.4%) for patients with a CRP between 4
and 20 mg/L and those with a CRP greater than 20 mg/L,
respectively (P ¼ .021). After adjustment with the patho-
logic stage, the association between worse survival and
CRP levels was maintained only between patients with un-
detectable CRP and patients with CRP greater than 20 mg/L
(P ¼ .018) and was lost between patients with a CRP be-
tween 4 and 20 (P ¼ .12) and those with an undetectable
CRP.DISCUSSION
This large study found that CRP level is an independent
predictor of long-term survival in patients with initial stagediovascular Surgery c Volume 142, Number 5 1165
TABLE 4. Adjusted hazard ratios calculated from the multivariate
analysis, taking into account the interaction between C-reactive
protein levels and pathologic stage
C-reactive protein level Stage I or II Stage III or IV
4–20 mg/L vs undetectable 1.364 (0.824–2.257) 0.722 (0.395–1.319)
>20 vs undetectable 1.874 (1.039–3.381) 0.492 (0.233–1.039)
Figures are hazard ratios with 95% confidence intervals. Adjustments were done for
age, propensity score for C-reactive protein greater than 20 mg/L, vascular and
lymphatic emboli, type of surgery, chronic bronchitis, American Society of Anesthe-
siologists score, albuminemia, smoking status, pathologic stage, and interaction
between C-reactive protein level and pathologic stage.
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Sresected NSCLC. This suggests that systemic inflammation
is related to outcome in these patients. These results are
based on the study of 2 cohorts from 2 different surgical
centers: in the first, preoperative and early postoperative
data were prospectively collected, whereas survival data
were retrospectively obtained; in the validation cohort,
both preoperative and postoperative data were collected
retrospectively.
Strengths and Limitations of the Study
In our opinion, a main strength of the study was the high
number of consecutive patients evaluated in the main cohort
with a standardized case report form that included a large
number of clinical and laboratory parameters that are not
usually measured in patients undergoing surgery for lung
cancer. On the other hand, the retrospective character of
the data collection prevented us from obtaining precise in-
formation on disease relapse after surgery. Overall survival,
rather than progression-free survival, was therefore evalu-
ated. Furthermore, missing data led us to exclude some
potentially eligible patients. This limitation concerned
only a minority of patients, however, and is therefore
unlikely to have affected the results.
Abnormal CRP values (>3 mg/L), indicating some de-
gree of systemic inflammation, were present in approxi-
mately half of operable patients with operable disease.
This parameter could thus constitute the basis for develop-
ment of specific management strategy in a significant pro-
portion of cases. In the Japanese study by Hara and
colleageus,15 only 38 out of the 203 surgically treated pa-
tients (18.7%) were found to have abnormal CRP values;
however, their cutoff was set at 5 mg/L.
CRP Levels and Tumor Size
In our experience, the number of patients with increased
CRP levels was relatively low in stage IA NSCLC (29%
and 33% in the main and validation cohorts, respectively)
but increased dramatically in stage IB (57% and 78% in
the main and validation cohorts, respectively). Although
this finding is in agreement with the known relationship be-
tween CRP levels and primary tumor burden,19 the prognos-
tic value of both CRP level and pT persisted in multivariate
analysis, suggesting that the predictive values of these 21166 The Journal of Thoracic and Cardiovascular Surfeatures are at least in part independent. As already reported
by others,19 we did not find a correlation between CRP and
pN and pM parameters.
CRP as a Prognostic Factor in Resected NSCLC
High CRP levels were a marker of poor prognosis in pa-
tients with stage I and II disease. Comparison with the avail-
able literature is difficult, because only a few studies have
assessed the prognostic value of CRP in resected lung can-
cer. In these studies,15,16 prognostic significance was
demonstrated in the whole population but an analysis per
stage was unavailable, probably because of the relatively
low number of patients in each category.
Underlying Mechanisms
In a large cohort study of 10,408 individuals, it was re-
cently shown that elevated CRP levels in cancer-free sub-
jects were associated with an increased risk of subsequent
occurrence of cancer, particularly lung cancer.4 The mech-
anisms underlying this association have not been eluci-
dated. In particular, the cohort studies do not allow one to
differentiate between whether systemic inflammation and
CRP levels are markers of occult cancer or are causally re-
lated to the malignancy.6 Amore recent analysis of the same
cohorts, however, based on the mendelian randomization
approach of 4 common single-nucleotide polymorphisms,
suggests that elevated CRP levels do not cause cancer per
se.20 Thus in cancer-free patients, high levels of CRP might
relate to occult cancers. Interestingly, in that study, in-
creased baseline CRP levels were associated with early
death after diagnosis of any cancer in patients without met-
astatic disease at diagnosis.4
In our study, CRP levels were significantly correlated
with tumoral vascular emboli. Blood vessel invasion is
known to be crucial for tumor spread, and it as been sug-
gested that vascular invasion could be an indicator of occult
metastases in early stages. Lee and associates19 also found
that tumor size and vascular invasion were independently
associated with CRP levels in a multiple linear regression
analysis. The mechanisms underlying this association re-
main poorly explained. The role of proinflammatory cyto-
kine secretion by endothelial cells encountering tumor
cells could be an interesting hypothesis.19
Other mechanisms explaining the prognostic role of CRP
have been advocated. CRP could be a marker of tumor pro-
duction of interleukin 6, which is known to block p53-
induced apoptosis.15 Thus increased CRP levels could be
amarker of the ability of tumors tomaintain amicroenviron-
ment suitable for the survival of remnant cells through the
upregulation of some acute inflammatory cytokines.15
Another possible explanation of the prognostic value of
CRP could be the relationship between systemic inflamma-
tion and nutritional status.7 Systemic inflammation has del-
eterious effects through the catabolic effects of cytokinesgery c November 2011
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Sand acute-phase proteins, which increase resting energy ex-
penditure. Indeed, in our experience prealbumin levels and
Prognostic Inflammatory and Nutrition Index (which corre-
lated negatively with CRP, data not shown) were predictors
of survival in univariate analysis, although their prognostic
value did not persist in multivariate analysis. This finding
suggests that nutritional derangement is a less robust deter-
minant of prognosis than is preoperative CRP level.
Perspectives
Patients with initial stage NSCLC are best treated with
surgery when possible, but at present there is no consensus
regarding the usefulness of postoperative follow-up. Re-
peated chest radiography, CT scan, fiberoptic bronchos-
copy, and positron emission tomographic scan have been
proposed, with enormous variations in medical resource
use and costs, as well as generation of patient stress. On
the other hand, adjuvant chemotherapy is known to improve
survival for patients with stage II or IIIa resected NSCLC,
although it provides no survival advantage for patients
with stage Ia disease. Results remain controversial for stage
Ib disease.21
Identification of patients with poor prognosis within a de-
termined stage would thus be useful for individual tailoring
of postoperative management. CRP measurement, together
with available clinicopathologic parameters, could help in
identifying patients requiring more aggressive manage-
ment. This potential utility remains to be formally demon-
strated in adequately designed studies.
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